Neogenomics Inc (NEO)
Sector: Industrials
Industry: Services-Testing Laboratories
Country: United States
Exchange: NASDAQ
Market cap: $2.56B
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Latest financial period: March 31, 2026
Filed with the SEC: April 28, 2026
Estimated earnings date: October 27, 2026
Profit #1265 of 1484 companies
| | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|
| ROE/ROA | 11.9% | 11.8% | 12.3% | 12.8% |
Growth #303 of 1484 companies
Payout #1117 of 1484 companies
Safety #898 of 1484 companies
Price #1374 of 1484 companies
